The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The Cobas Integra 800 is a blood test that measures a patient's average blood sugar level over the previous three months. In particular, the test measures an oxygen-carrying blood component known as hemoglobin.
The Food and Drug Administration said Thursday it approved a new blood test...
The Food and Drug Administration said Thursday it approved a new blood test...
Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop...
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Roche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche’s investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). It is estimated that over 10 million patients in China are chronically infected with HCV. The majority of these are genotype 1b, which has proven highly responsive to danoprevir.
Strong sales of new cancer drugs and a severe U.S. flu season helped lift first-quarter revenue at Swiss drugmaker Roche Holding AG by 6 percent. The world's biggest manufacturer of cancer drugs said that sales rose to 11.56 billion Swiss francs ($12.4 billion) during the first three months of the year, up from 11.03 billion francs in the same period last year.
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Galapagos NV announced today that it agreed with Roche to end their alliance in fibrosis. Roche will make a payment of EUR5.75 million to Galapagos for work completed in 2012, contributing to 2012 Group revenues. With the ending of the alliance, Galapagos has regained the worldwide rights to all fibrosis assays and the targets discovered in the alliance.
Swiss drugmaker Roche Holding AG says its chairman, Franz Humer, will step down next year after 13 years. The 66-year-old Humer announced at the company's annual general meeting Tuesday that he won't stand for re-election to the board in 2014. The company said it will nominate a successor this fall.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together.
Roche and Chiasma Announce Collaboration to Develop and Commercialize Chiasma's Octreolin for Acromegaly and Neuroendocrine TumorsFebruary 19, 2013 8:03 am | News | Comments
Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection.
The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year. The FDA said in an online post Tuesday that at least one batch of the drug distributed by a New York company does not contain the active ingredient in real Avastin.
Roche announced today the global launch and availability of a new comprehensive suite of SeqCap EZ Reagent kits for application in single or multiplex target enrichment experiments prior to DNA Sequencing.
The Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
Genentech, a member of the Roche Group has announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin ® (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).
cobas IT middleware enables the total automated laboratory. Roche enhances its lineup of IT solutions for the professional medical laboratory and today unveils cobas IT middleware, a software suite for fully automated workflow management. Enabling laboratory managers to easily link...
Roche and PSS sign agreement to develop a fully automated workflow solution for next-generation sequencing platformsDecember 23, 2012 6:22 pm | by Roche | News | Comments
Roche and Precision System Science, Co., Ltd (PSS) today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche’s portfolio of next-generation sequencing platforms. It is intended to support Roche’s GS...
Roche & #039;s rapid mycoplasma detection test MycoTOOL receives FDA acceptance for release testing of biopharmaceutical Roche productDecember 19, 2012 6:23 pm | by Roche | News | Comments
First commercially available mycoplasma PCR test accepted by FDA reduces time for detection from one month to one day. Today Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the use of its PCR based mycoplasma detection test MycoTOOL for release testing of one...
Roche 454 Sequencing Systems successfully resolve genetic mutations in over 4,000 blood cancer casesDecember 11, 2012 3:22 am | by Roche | News | Comments
International study presented at American Society of Hematology Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions. At the American Society of Hematology Meeting (ASH)...
Roche announced today that its cancer drug Zelboraf (vemurafenib) won the Best New Drug award at the 2012 Scrip Awards ceremony held in London last night.
Roche announced today the launch and immediate availability of a new software package (v2.8) that significantly improves long-read shotgun sequencing performance on its GS FLX+ System.
Roche and Agilent Technologies Establish Agreement to Provide Continued Service and Support to Roche NimbleGen Microarray CustomersNovember 14, 2012 5:23 pm | by Roche | News | Comments
Roche and Agilent Technologies, Inc. today announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production and services.
Roche launches additional test for improved management of epithelial ovarian cancer patients in the U.S.November 14, 2012 5:23 pm | by Roche | News | Comments
Roche announced today the U.S. market availability of the Elecsys HE4 assay, an FDA approved test used in monitoring patients with ovarian cancer. The HE4 test is used as an aid in monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer.
LONDON (AP) — A leading British medical journal is asking the drug maker Roche to release all its data on Tamiflu, claiming there is no evidence the drug can actually stop the flu.
Today Roche announced the global launch of its new High Pure FFPET RNA Isolation Kit as well as the RealTime ready cDNA Pre-Amp Master & Primer Pools. Formalin-fixed, paraffin-embedded tissue (FFPET) samples from biopsies or micro-dissections are frequently used for retrospective...
Today Roche announced the global launch of its Cedex Bio HT Analyzer for the highly reliable determination of metabolites and substrates in mammalian and microbial cell fermentation. The Cedex Bio HT System offers very precise analytics, a broad test portfolio allowing flexible adaption...